Completed PHASE1 INTERVENTIONAL 2-arm NCT05515458

Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function

Study to Evaluate the Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function

Sponsor: Chipscreen Biosciences, Ltd.

Interventions Chiglitazar

Updated 5 times since 2022 Last updated: May 24, 2024 Started: Nov 20, 2022 Primary completion: Jul 19, 2023 Completion: Jul 19, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Renal Impairment and is currently completed. Chipscreen Biosciences, Ltd. leads this study, which shows 5 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2024 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Mar 2023 — Jun 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Sep 2022 — Mar 2023 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chipscreen Biosciences, Ltd.

Data source: Chipscreen Biosciences, Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Suzhou, China